Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
sulfonamide
C12H14ClN3O2S |
| gptkbp:clinicalTrials |
Phase 2
Phase 3 treatment of infections included in treatment guidelines |
| gptkbp:composedOf |
chemical synthesis
|
| gptkbp:contraindication |
fever
diarrhea rash allergy to sulfonamides |
| gptkbp:developedBy |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:dissolved |
soluble in water
soluble in ethanol |
| gptkbp:dosageForm |
tablet
injection |
| gptkbp:drugInterdiction |
warfarin
methotrexate |
| gptkbp:evaluates |
effective against Gram-negative bacteria
effective against Gram-positive bacteria |
| gptkbp:financial_aid |
stable under normal conditions
|
| gptkbp:future_plans |
clinical trials
|
| gptkbp:healthcare |
advised on dosage
informed about side effects instructed on administration |
| https://www.w3.org/2000/01/rdf-schema#label |
WPC-350
|
| gptkbp:interactsWith |
other antibiotics
|
| gptkbp:market |
available
|
| gptkbp:marketedAs |
brand name A
brand name B |
| gptkbp:patentStatus |
patented
|
| gptkbp:regulatoryCompliance |
approved
monitored |
| gptkbp:researchAreas |
ongoing research
|
| gptkbp:researchFocus |
antibiotic resistance
combination therapies new formulations |
| gptkbp:route |
oral
intravenous |
| gptkbp:safetyFeatures |
generally safe
|
| gptkbp:sideEffect |
dizziness
headache nausea |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
children
adults bacterial infections |
| gptkbp:triggerType |
inhibits bacterial cell wall synthesis
|
| gptkbp:usedIn |
pharmaceuticals
|